Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

bioAffinity Technologies, Inc. (BIAF) vs XWELL, Inc. (XWEL)

bioAffinity Technologies, Inc. and XWELL, Inc. are both Diagnostics & Research companies. bioAffinity Technologies, Inc. is the larger, with a market value of $9.0M against $7.6M — 1.2× the size. XWELL, Inc. grew revenue faster over the last twelve months: −7.58% against −23.2%. XWELL, Inc. has the higher net margin (−117.8% vs −257.3%) and the higher return on invested capital (0.00% vs −408.7%). Across the 17 metrics below, XWELL, Inc. leads on 13 and bioAffinity Technologies, Inc. on 4.

Valuation

Metric BIAF XWEL Diagnostics & Research median
P/E n/m n/m 33.95
P/S 0.47 0.27 4.87
P/B 0.73 0.92 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m n/m 25.20
EV/Sales 0.15 0.30 5.66
Earnings yield (1,380.14%) (597.75%) (1.75%)
Free cash flow yield (418.18%) (178.41%) (0.13%)

Profitability

Metric BIAF XWEL Diagnostics & Research median
Gross margin 34.61% 34.34% 50.89%
Operating margin (209.82%) (61.31%) (8.57%)
Net margin (257.33%) (117.83%) (6.37%)
Free cash flow margin (195.90%) (47.65%) 0.00%
Return on equity (1,860.15%) (557.21%) (2.92%)
Return on assets (245.51%) (155.10%) (6.71%)
Return on invested capital (408.67%) 0.00% 0.00%

Growth

Metric BIAF XWEL Diagnostics & Research median
Revenue growth (TTM) (23.18%) (7.58%) 7.69%
EPS growth (last fiscal year) 61.55% (38.80%) —
Revenue growth, 5-year CAGR — 28.35% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BIAF XWEL Diagnostics & Research median
Debt to equity 0.15 0.00 0.11
Current ratio 1.44 2.27 2.02
Net debt to EBITDA 0.57 (0.08) 0.78

Dividend

Metric BIAF XWEL Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio — 0.00 0.00

Size

Metric BIAF XWEL Diagnostics & Research median
Market cap 9.00m 7.64m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack